Market closedNon-fractional
Protagonist Therapeutics/PTGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Protagonist Therapeutics
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Ticker
PTGX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Newark, United States
Employees
124
Website
www.protagonist-inc.com
PTGX Metrics
BasicAdvanced
$2.4B
Market cap
15.38
P/E ratio
$2.70
EPS
2.08
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
2.08
Financial strength
Current ratio
15.724
Quick ratio
15.611
Total debt to equity
0.082
Management effectiveness
Return on assets (TTM)
21.38%
Return on equity (TTM)
41.75%
Valuation
Price to earnings (TTM)
15.377
Price to revenue (TTM)
7.831
Price to book
4.32
Price to tangible book (TTM)
4.32
Price to free cash flow (TTM)
-38.444
Growth
Revenue change (TTM)
36,565.08%
Earnings per share change (TTM)
-195.36%
3-year revenue growth (CAGR)
116.19%
3-year earnings per share growth (CAGR)
14.12%
What the Analysts think about PTGX
Analyst Ratings
Majority rating from 6 analysts.
PTGX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$255M
324.83%
Net income
$207M
659.34%
Profit margin
81.32%
78.73%
PTGX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.68
-$0.58
$0.44
$3.26
-
Expected
-$0.65
-$0.69
-$0.03
$1.19
-$0.60
Surprise
5.05%
-16.41%
-1,425.30%
173.08%
-
PTGX News
AllArticlesVideos
Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024
Accesswire·5 days ago
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
Accesswire·2 months ago
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protagonist Therapeutics stock?
Protagonist Therapeutics (PTGX) has a market cap of $2.4B as of July 26, 2024.
What is the P/E ratio for Protagonist Therapeutics stock?
The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 15.38 as of July 26, 2024.
Does Protagonist Therapeutics stock pay dividends?
No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Protagonist Therapeutics dividend payment date?
Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Protagonist Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.